대한신장학회

논문분류	춘계학술대회 초록집
제목	Circulating Irisin Level in Human Diabetic Cohorts; 11 Year Retrospective Cohort Study
저자	Jin Joo Cha1, Mi Jin Lee1, Hye Sook Min1, Mi Hwa Lee1, Hye Kyoung Song1, Jung Eun Kim1,Nan Hee Kim2, Young Youl Hyun3, Dae Ryong Cha1, Young Sun Kang1
출판정보	2013; 2013(1):
키워드	당뇨, 아이리신, CKD EPI/Diabetes, Irisin, CKD EPI
초록	Objective: Irisin, a novel myokine which is proteolytically processed from the product of the FNDC5 gene, has been proposed to mediate beneficial effects on metabolism by inducing browning of subcutaneous adipocytes and upregulation of uncoupling protein1 level in experimental mice. In humans, circulating irisin level was significantly decreased in obese and diabetic patients. However, the role of irisin in humans is not clearly elucidated. We therefore, examined circulating irisin level and its associations with various complications of diabetes. Methods: We performed a retrospective cohort analysis of 161 diabetic individuals followed up for approximately 11 years. Baseline circulating plasma level of irisin was measured using commercially available EIA kit (Phoenix pharmaceuticals (ng/ml)). The associations between the circulating irisin with variable metabolic parameters, microvascular and macrovascular complications were evaluated. Results: Total 161 patients (n=14, type 1 diabetes, n=147 type 2 diabetes, mean age 43,6±4.6, 66.8±10.4 respectively) were analyzed. There were no significant associations with circulating irisin levels with gender difference, the type of diabetes, body mass index, age, Patients with hypertension (n= 66) showed significantly decreased level of circulating irisin (649.09±661.9 vs 884.01±792.27, p=0.04). There was no significant difference in irisin level among the CKD stages (using CKD-EPI equation), however there was a trend toward decrement as the stage advanced. (stage 1 (n=62) 806.97±793.70, stage 2 (n=58) 925.31±849.83, stage 3a (n=20) 690.75±522.96, stage 3b (n=12) 547.5± 460.7, stage 4 (n=5) 627.30±464.73, stage 5 (n=4) 207.48±75.89). Binary logistic regression was performed to evaluate the relative risks of irisin level with the development of micro- and macrovascular complications. The irisin level did not affect the risks of macrovascular complications. However, increased level of irisin (log irisin) significantly decreased the risk of retinopathy (Unadjusted RR 0.688, 95% CI 0.516-0.918, p=0.01, Adjusted RR 0.677, 95% CI 0.487-0.942, p=0.02). Discussion: Circulating irisin level of diabetic patients was not affected by renal insufficiency nor did not affect diabetic nephropathy. It might have a predictive role in diabetic retinopathy.
원문(PDF)	PDF 원문보기

간행물 검색

대한신장학회 회원관리 규정